Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF

• US 7,557,195 B2
• Filed: 03/20/2003
• Issued: 07/07/2009
• Est. Priority Date: 03/20/2002
• Status: Expired due to Fees

• Current Assignee: BiopolyMed, Inc.
• Original Assignee: BiopolyMed, Inc.
• Inventors: Park, Myung-Ok
• Primary Examiner(s): Spector; Lorraine
• Assistant Examiner(s): Stoica; Elly-Gerald
• Application Number:
  US10/508,721
• Publication Number:
  US 20050143563A1
• Time in Patent Office: 2,301 Days
• Field of Search: None
• US Class Current: 530/399
• CPC Class Codes: C07K 14/535 Granulocyte CSF; Granulocyte-macrophage CSF

Abstract

The present invention relates to a conjugate of a biocompatible polymer and a G-CSF bonded through a thiol group of a dysteine residue in G-CSF at a 1:1 molar ratio, and methods of preparation thereof.

Claims

1. A conjugate of a biocompatible polymer and wild type G-CSF, wherein the activated biocompatible polymer is bonded to wild type G-CSF at a 1:

1 molar ratio through a thiol group of a cysteine residue free of disulfide bonds corresponding to the position 17 (C17) of the mature human wild-type G-CSF.

2. The conjugate according to claim 1, wherein the biocompatible polymer is selected from the group consisting of polyethylene glycol (PEG) and derivatives thereof, polypropylene glycol (PPG), polyoxyethylene (POE), polytrimethylene glycol, polylactic acid and derivatives thereof, polyacrylic acid and derivatives thereof, polyamino acid, poly(vinyl alcohol), polyurethane, polyphosphazene, poly(L-lysine), polyalkylene oxide (PAO), polysaccharide, dextran, polyvinyl pyrrolidone, polyvinyl alcohol (PVA), polyacryl amide and similar non-immunogenic polymers.

3. The conjugate according to claim 1, wherein the wild type G-CSF originates and is purified from a natural or recombinant protein source.

4. The conjugate according to claim 1, wherein the reactive functional group in the biocompatible polymer for activation is selected from the group consisting of maleimide, acetamide, pentenoic amide, butenoic amide, isocyanate, isothiocyanate, cyanuric chloride, 1,4-benzoquinone, and disulfide.

5. The conjugate according to claim 1, wherein the biocompatible polymer is selected from the group consisting of polyethylene glycol (PEG) and derivatives thereof.

6. The conjugate according to claim 1, wherein the biocompatible polymer is selected from the group consisting of polyethylene glycol (PEG)s.

7. The conjugate according to claim 1, wherein the reactive functional group in the biocompatible polymer for activation is maleimide.

8. The conjugate according to claim 1, wherein the reactive functional group in the biocompatible polymer for activation is disulfide.

9. The conjugate according to claim 1, wherein the biocompatible polymer has a molecular weight of between 2,000 and 40,000 Daltons.

10. A conjugate of a biocompatible polymer and wild type G-CSF that has a methionine residue at position 1, wherein the activated biocompatible polymer is bonded to wild type G-CSF at a 1:

1 molar ratio through a thiol group of a cysteine residue free of disulfide bonds corresponding to the position 17 (C17) of the mature human wild-type G-CSF.